Business Context and Reporting Period
Company: Actuate Therapeutics, Inc. (ACTU)
Filing Type: Form 8-K (Current Report)
Date of Report: May 31, 2025
Event: Disclosure of topline Phase 2 clinical trial data for elraglusib in combination with gemcitabine/nab-paclitaxel (GnP) for first-line treatment of metastatic pancreatic cancer (mPDAC). The data was presented at the American Society of Clinical Oncology (ASCO) 2025 Annual Meeting.
Key Financial Metrics
This filing is a Current Report (8-K) focused on clinical trial results and does not contain audited financial statements, revenue, profit, cash flow, or debt figures for the reporting period.
Liquidity Status: The filing explicitly states that the Company's financial condition raises "substantial doubt as to its ability to continue as a going concern." The Company requires additional capital to finance operations beyond the second quarter of fiscal year 2025.
Material Changes and Clinical Results
The primary material change is the announcement of positive topline results from the Actuate-1801 Part 3B Phase 2 trial (NCT03678883) as of March 27, 2025. The study compared elraglusib/GnP versus GnP alone in 286 patients.
| Metric | Elraglusib/GnP (n=155) | GnP Alone (n=78) | Statistical Significance |
|---|---|---|---|
| Median Overall Survival (mOS) | 10.1 months | 7.2 months | HR=0.63; p=0.01 |
| 12-Month OS Rate | 44.1% | 22.3% | p=0.0005 |
| 18-Month OS Rate | 19.7% | 4.4% | N/A |
| 24-Month OS Rate | 13.8% | 0% | N/A |
| Overall Response Rate (ORR) | 29.0% | 21.8% | Numerical improvement |
| Median Progression-Free Survival (PFS) | 5.6 months | 5.1 months | Numerical improvement |
| Disease Control Rate (DCR) | 61.3% | 56.4% | Numerical improvement |
Safety Profile: The trial met its primary safety endpoint. Treatment-emergent adverse events were similar between arms. The most frequent treatment-related adverse events were transient, reversible visual impairments (approx. 66% of patients). Rates of febrile neutropenia and sepsis were similar in both arms.
Guidance, Outlook, and Risks
- Outlook: The Company hosted a Key Opinion Leader (KOL) event to review the data. Management highlighted a 37% reduction in the risk of death with the combination therapy.
- Capital Needs: The Company requires additional capital to fund operations beyond Q2 2025. Failure to secure this capital could force delays or termination of development programs.
- Risks:
- Data is preliminary and subject to change upon full analysis.
- Clinical trial results are not necessarily predictive of future results or regulatory approval.
- Substantial doubt exists regarding the Company's ability to continue as a going concern.
- Reliance on third parties for clinical trials and intellectual property.
Investor Verification Checklist
- Capital Runway: Verify the Company's current cash position and the status of any financing efforts to address the "substantial doubt" regarding going concern status.
- Data Finalization: Confirm when the full data analysis will be completed and if the preliminary topline numbers (mOS, OS rates) remain consistent.
- Regulatory Path: Monitor communications with the FDA and EMA regarding the design of potential Phase 3 trials based on these Phase 2 results.
- Safety Monitoring: Review the full safety data regarding transient visual impairments and neutropenia to assess long-term tolerability.